NewEdge Advisors’s NovoCure NVCR Stock Holding History

NewEdge Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-130	Closed	-$2.31K	–	4204
2025 Q2	$2.31K	Hold	130	–	–	﹤0.01%	3588
2025 Q1	$2.32K	Hold	130	–	–	﹤0.01%	3479
2024 Q4	$3.87K	Hold	130	–	–	﹤0.01%	3298
2024 Q3	$2.03K	Hold	130	–	–	﹤0.01%	3380
2024 Q2	$2.23K	Hold	130	–	–	﹤0.01%	3309
2024 Q1	$2.03K	Hold	130	–	–	﹤0.01%	3366
2023 Q4	$1.94K	Hold	130	–	–	﹤0.01%	3344
2023 Q3	$2.1K	Hold	130	–	–	﹤0.01%	3035
2023 Q2	$5.39K	Hold	130	–	–	﹤0.01%	2786
2023 Q1	$7.82K	Sell	130 -115	-47%	-$9.19K	﹤0.01%	2643
2022 Q4	$8.22K	Buy	+245	New	+$18.4K	﹤0.01%	2431
2020 Q4	–	Sell	-3,699	Closed	-$412K	–	1055
2020 Q3	$412K	Buy	+3,699	New	+$296K	0.01%	632
2020 Q2	–	Sell	-3,108	Closed	-$209K	–	922
2020 Q1	$209K	Buy	+3,108	New	+$246K	0.01%	694

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NewEdge Advisors's NVCR Position: Q3 2025 in Review

NewEdge Advisors sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 130 shares — an estimated $2.31K sold.

NewEdge Advisors first reported a position in NVCR in Q1 2020 and held it in 13 quarters. The position peaked at $412K in Q3 2020. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

NewEdge Advisors reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
NewEdge Advisors sold 130 NovoCure shares in Q3 2025, an estimated $2.31K.
NewEdge Advisors first reported a position in NovoCure in Q1 2020 and held it in 13 quarters.
NewEdge Advisors's NovoCure position peaked at $412K in Q3 2020.
244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.